← Feed

Kelly Thomas Patrick

SEC Form 4 insider
Chief Financial Officer · Xenon Pharmaceuticals Inc. ($XENE)
1 thesis · first seen Oct 1, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d——————
3d——————
1w——————
1m——————
3m——————
6m——————
1y——————

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$XENESEC Form 4bullish
Kelly Thomas Patrick · Chief Financial Officer at Xenon Pharmaceuticals Inc. · 3h agono track record yet
Long 15,000 shares of XENE
Bought 15,000 @ $37.32 avg · $559,740 · 2026-09-30

Form 4: Kelly Thomas Patrick bought XENE

Kelly Thomas Patrick (Chief Financial Officer at Xenon Pharmaceuticals Inc.) reported an open-market purchase of 15,000 shares of XENE at an average $37.32, roughly $559,740, in a Form 4 filed 2026-10-01.

Now $39.75as of Sep 18, 4:31 PM ET
View filing on SEC.gov →

End of results.